![]() | Only 14 pages are availabe for public view |
Abstract Chronic kidney disease (CKD) is increasingly categorized as a worldwide public health dispute with adverse outcomes on patients’ health and huge financial burden. Once nephropathy develops, approximately 20–40% of patients step forward to ESRD. Therefore, novel biomarkers are needed to enable early risk recognition in diabetic nephropathy, so that those at advanced risk of progression to ESRD are identified at early stages of nephropathy development. Thus, the aim of the present work was to study the levels of fibroblast growth factor 23 (FGF23) in type 2 diabetic patients with different stages of diabetic kidney disease and to evaluate its diagnostic value as a biomarker for early detection of diabetic kidney disease in comparison with albuminuria. The current study was carried out on 85 individuals who attended to outpatient clinics of Internal medicine department at El-Menoufia university hospital during the period from April 2018 to April 2019. The selected subjects were divided into three groups: group I included 10 healthy normal non diabetic control subjects, group II included 25 patients who had type 2 diabetes mellitus with normoalbuminuria, group III included subjects who had diabetic kidney disease and subdivided into 2 sections: 25 Subjects with type 2 DM with microalbuminuria & 25 Subjects with type 2 DM with macroalbuminuria. As regard the results of serum FGF23, there was progressively increase in the mean level of FGF23 in diabetic groups. Where, the mean levels of FGF23 in normoalbuminuric, microalbuminuric and macroalbuminuric group were 171.4±30.09, 337.8±55.72 and 794.4±185 (pg /ml) respectively compared to controls of 98.5±12.92 (pg /ml). The ANOVA test showed statistically significant difference in the mean level of FGF23 among different diabetic groups and in diabetic groups more than controls. |